Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1479-5876

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis ; volume:9 ; number:2 ; day:23 ; month:11 ; year:2011 ; pages:1 ; date:12.2011
Journal of translational medicine ; 9, Heft 2 (23.11.2011), 1, 12.2011

Creator: Balak, Deepak MW

Contributor: Hengstman, Gerald JD
Hupperts, Raymond
Thio, H Bing
SpringerLink (Online service)

DOI: 10.1186/1479-5876-9-S2-P14

URN: urn:nbn:de:1111-2016041439268

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Balak, Deepak MW
Hengstman, Gerald JD
Hupperts, Raymond
Thio, H Bing
SpringerLink (Online service)

Other Objects (12)

Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events

Aufsatzsammlung

Adverse cutaneous drug eruptions : 34 tables

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events

Aufsatzsammlung

Adverse cutaneous drug eruptions : 34 tables

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events

Aufsatzsammlung

Adverse cutaneous drug eruptions : 34 tables

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events

Adverse cutaneous drug eruptions : 34 tables

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events

Adverse cutaneous drug eruptions : 34 tables

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events

Adverse cutaneous drug eruptions : 34 tables

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Related objects

Reset password